Gaudium IVF IPO is a book-built issue worth ₹165.00 crores, consisting of a fresh issue of ₹90.00 crores and an offer for sale of ₹75.00 crores. The IPO opens on February 20, 2026, and closes on February 24, 2026, with tentative listing on BSE and NSE on February 27, 2026.
The IPO is priced in the range of ₹75 to ₹79 per share, with a minimum investment of ₹14,931 for retail investors. Gaudium IVF & Women Health Ltd. operates in the fertility and reproductive healthcare segment, offering IVF and allied treatments across India.
Let us understand the Gaudium IVF IPO in detail.
The following are some of the important and key details about the Gaudium IVF IPO.
The following table explains the tentative IPO schedule.
Event | Date |
IPO Opens | Feb 20, 2026 |
IPO Closes | Feb 24, 2026 |
Allotment | Feb 25, 2026 |
Refunds | Feb 25, 2026 |
Credit of Shares | Feb 26, 2026 |
Listing Date | Feb 27, 2026 |
The following table shows the minimum and maximum investment required.
Category | Shares | Amount |
Retail (Min) | 189 | ₹ 14,931 |
Retail (Max) | 2,457 | ₹ 1,94,103 |
sHNI (Min) | 2,646 | ₹ 2,09,034 |
sHNI (Max) | 12,474 | ₹ 9,85,446 |
bHNI (Min) | 12,663 | ₹ 10,00,377 |
Incorporated in March 2015, Gaudium IVF & Women Health Limited is engaged in providing In Vitro Fertilization (IVF) treatments across India. The company has expanded into multiple states using a hub-and-spoke operating model.
The company operates more than thirty locations, including seven hubs and twenty-eight spokes. It has also entered into strategic alliances with infertility experts to increase awareness around Assisted Reproductive Technology (ART) and IVF treatments.
Gaudium IVF serves patients from multiple international geographies, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
Its centres are located across key Indian cities, including:
The company provides specialized fertility and reproductive treatments, including:
It also offers comprehensive gynaecological care for:
Additionally, the company provides advanced male infertility treatments, including sperm retrieval procedures.
The following are the key strengths of the company:
The following table shows restated consolidated financials:
The following explains how IPO proceeds will be used:
Market Capitalisation: ₹575.02 Cr
Promoter Holding: 99.99% (Pre-IPO) → 71.30% (Post-IPO)
The promoters of the company are:
Gaudium IVF & Women Health Ltd. operates in the fertility treatment and reproductive healthcare segment, offering IVF and related services through a hub-and-spoke centre network across India. The company has expanded its presence across major cities and also caters to international patients.
The business model focuses on specialized fertility treatments, gynaecological care, and male infertility solutions supported by medical expertise and laboratory infrastructure. IPO proceeds are proposed to be utilized toward new centre expansion and loan repayment.
Also, we have a dedicated article on upcoming IPOs in february 2026, wherein you can check all the IPOs that were launched in february 2026 along with upcoming IPOs for february 2026.
This content is for informational and educational purposes only and does not constitute investment advice. UnlistedKraft is not responsible for any losses arising from investment decisions based on this content. Readers should conduct their own research and consult qualified professionals before investing. IPO is expected to list on Feb 27, 2026, on BSE and NSE.
Gaudium IVF IPO is a main-board IPO of ₹165.00 crore comprising fresh issue and offer for sale, priced at ₹75–₹79 per share.
The IPO opens on February 20, 2026, and closes on February 24, 2026.
The minimum lot size is 189 shares.
The allotment is expected to be finalized on February 25, 2026.
The tentative listing date is February 27, 2026.
Bigshare Services Pvt. Ltd. is the registrar of the issue.
Diwakar Kumar Singh is a finance writer and BFSI specialist with 7+ years of experience in financial content and research. He has authored hundreds of finance articles, published multiple books internationally, and contributed to research publications. A Gold Medalist MBA from IMT, he brings a strong analytical understanding combined with clear, reader-focused communication. His work focuses on simplifying complex financial topics, including IPO analysis, unlisted shares, financial ratios, and company evaluations, providing well-researched and evidence-based insights to help readers make informed financial decisions.
Drop a Mail or give us a Missed Call & Begin your Investment Journey here